Opioid system in L-DOPA-induced dyskinesia

被引：0
作者：
Jing Pan
Huaibin Cai
机构：
[1] Transgenics Section,
[2] Laboratory of Neurogenetics,undefined
[3] National Institute on Aging,undefined
[4] National Institutes of Health,undefined
来源：
Translational Neurodegeneration | / 6卷
关键词：
Basal Ganglion; Opioid Receptor; Opioid Peptide; Globus Pallidus Internal; Opioid Receptor Antagonist;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
L-3, 4-Dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) is a major clinical complication in the treatment of Parkinson’s disease (PD). This debilitating side effect likely reflects aberrant compensatory responses for a combination of dopaminergic neuron denervation and repeated L-DOPA administration. Abnormal endogenous opioid signal transduction pathways in basal ganglia have been well documented in LID. Opioid receptors have been targeted to alleviate the dyskinesia. However, the exact role of this altered opioid activity is remains under active investigation. In the present review, we discuss the current understanding of opioid signal transduction in the basal ganglia and how the malfunction of opioid signaling contributes to the pathophysiology of LID. Further study of the opioid system in LID may lead to new therapeutic targets and improved treatment of PD patients.
引用
收藏
相关论文
共 259 条
[1]  
Langston JW(2002)Parkinson’s disease: current and future challenges Neurotoxicology 23 443-50
[2]  
Trojanowski JQ(2002)Parkinson’s disease and related synucleinopathies are a new class of nervous system amyloidoses Neurotoxicology 23 457-60
[3]  
Lee VM(2005)The ‘magic’ of L-dopa: why is it the gold standard Parkinson’s disease therapy? Trends Pharmacol Sci 26 341-4
[4]  
Mercuri NB(2016)Drug-induced dyskinesia, Part 1: treatment of levodopa-induced dyskinesia Drugs 76 759-77
[5]  
Bernardi G(2014)Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications Front Neurol 5 242-76
[6]  
Vijayakumar D(2010)Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment Mov Disord 25 1568-168
[7]  
Jankovic J(2015)Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease Prog Neurobiol 132 96-46
[8]  
Cenci MA(2004)Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson’s disease: implications for dyskinesia Exp Neurol 185 36-14
[9]  
Belujon P(2012)Endogenous opioid systems: current concepts and clinical correlations Neurology 79 807-7
[10]  
Lodge DJ(2006)Opioids and motor complications in Parkinson’s disease Trends Pharmacol Sci 27 512-20
12345678910